Mechanistically, the piENOX2 inhibitor stabilized ALKBH5 expression, reducing Itga4 m6A modifications, sustaining PI3K–AKT pathway activation and thereby promoted macrophage M2 polarization and slowed the progression of RA. Here, ALKBH5 is linked to rheumatoid arthritis.